A study to evaluate how safe and effective 0.5 mg fingolimod is in delaying disability progression if taken once daily, in patients with PPMS
efficacy and safety of 0.5 mg fingolimod in patients with primary progressive multiple sclerosis
- Registry ID
- EUCTR2007-002627-32
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- Novartis Pharma AG
- Start date
- 2010-11-29
- Completion date
- 2014-09-02
- Last update
- 2026-08-16
Conditions
- Esclerosis múltiple primaria progresiva.
- primary progressive multiple sclerosis
- Primary progressive multiple sclerosis.
Summary
To evaluate the effect of 0.5 mg fingolimod relative to placebo on delaying the time to sustained disability progression.
Locations
- , , Germany
- , , Czechia
- , , Spain
- , , Sweden
- , , France
- , , Finland
- , , Netherlands
- , , Italy
- , , UK
- , , Belgium
- , , Hungary
- , , Denmark
View on source registry